ME03476B - Nefukozilisana anti-fgfr2iiib antitijela - Google Patents

Nefukozilisana anti-fgfr2iiib antitijela

Info

Publication number
ME03476B
ME03476B MEP-2019-142A MEP2019142A ME03476B ME 03476 B ME03476 B ME 03476B ME P2019142 A MEP2019142 A ME P2019142A ME 03476 B ME03476 B ME 03476B
Authority
ME
Montenegro
Prior art keywords
afucosylated anti
fgfr2iiib antibodies
fgfr2iiib
antibodies
afucosylated
Prior art date
Application number
MEP-2019-142A
Other languages
German (de)
English (en)
French (fr)
Inventor
Thomas Harding
Kristen Pierce
Namrata Patil
Thomas Brennan
Julie Hambleton
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03476(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of ME03476B publication Critical patent/ME03476B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2019-142A 2013-08-01 2014-07-31 Nefukozilisana anti-fgfr2iiib antitijela ME03476B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361861198P 2013-08-01 2013-08-01
US201361901732P 2013-11-08 2013-11-08
US201461933632P 2014-01-30 2014-01-30
EP14752705.5A EP3027651B1 (en) 2013-08-01 2014-07-31 Afucosylated anti-fgfr2iiib antibodies
PCT/US2014/049008 WO2015017600A1 (en) 2013-08-01 2014-07-31 Afucosylated anti-fgfr2iiib antibodies

Publications (1)

Publication Number Publication Date
ME03476B true ME03476B (me) 2020-01-20

Family

ID=51358085

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-142A ME03476B (me) 2013-08-01 2014-07-31 Nefukozilisana anti-fgfr2iiib antitijela

Country Status (30)

Country Link
US (5) US20150050273A1 (me)
EP (3) EP3027651B1 (me)
JP (5) JP6860342B2 (me)
KR (3) KR102825701B1 (me)
CN (2) CN112225810B (me)
AU (4) AU2014296174B2 (me)
CA (1) CA2915665C (me)
CL (2) CL2016000221A1 (me)
CY (2) CY1121517T1 (me)
DK (2) DK3027651T3 (me)
ES (2) ES2913291T3 (me)
HR (1) HRP20190502T1 (me)
HU (2) HUE058243T2 (me)
IL (1) IL243409B (me)
LT (2) LT3027651T (me)
ME (1) ME03476B (me)
MX (2) MX374785B (me)
MY (1) MY184628A (me)
NZ (1) NZ715201A (me)
PE (2) PE20210949A1 (me)
PH (3) PH12019501393B1 (me)
PL (2) PL3027651T3 (me)
PT (2) PT3708583T (me)
RS (1) RS58719B1 (me)
RU (2) RU2740714C2 (me)
SG (1) SG11201600767UA (me)
SI (2) SI3027651T1 (me)
TW (2) TWI679021B (me)
WO (1) WO2015017600A1 (me)
ZA (1) ZA201603218B (me)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3027651T3 (pl) 2013-08-01 2019-08-30 Five Prime Therapeutics, Inc. Afukozylowane przeciwciała anty-fgfr2iiib
WO2015067547A1 (en) * 2013-11-05 2015-05-14 Roche Diagnostics Gmbh A method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
KR20250034528A (ko) * 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
RS67296B1 (sr) 2017-05-16 2025-11-28 Five Prime Therapeutics Inc Anti-fgfr2 antitela u kombinaciji sa sredstvima za hemoterapiju u lečenju karcinoma
AU2018268970B2 (en) 2017-05-19 2024-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
CR20200138A (es) * 2017-08-25 2020-06-14 Five Prime Therapeutics Inc Anticuerpos de b7-h4 y métodos para usarlos
CA3091174A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR102863169B1 (ko) 2018-02-21 2025-09-22 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 투약 섭생법
EP3759142A1 (en) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
BR112021007134A2 (pt) 2018-10-15 2021-08-10 Five Prime Therapeutics, Inc. terapia combinada para câncer
WO2021129655A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
AR120886A1 (es) * 2019-12-24 2022-03-30 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
MX2022007960A (es) * 2019-12-24 2022-07-12 Dizal Jiangsu Pharmaceutical Co Ltd Nuevos anticuerpos anti-fgfr2b.
AU2021232158A1 (en) 2020-03-06 2022-09-29 Ona Therapeutics, S.L. Anti-CD36 antibodies and their use to treat cancer
WO2022087243A1 (en) * 2020-10-22 2022-04-28 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
US20240101683A1 (en) * 2020-12-29 2024-03-28 Shenzhen Forward Pharmaceuticals Co., Limited Anti-FGFR2 Antibody and Use Thereof
EP4377344A1 (en) 2021-07-30 2024-06-05 Ona Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
EP4414387A4 (en) * 2021-10-08 2025-10-29 Shenzhen Forward Pharmaceuticals Co Ltd ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
EP4594356A1 (en) * 2022-09-30 2025-08-06 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
TW202442679A (zh) * 2022-12-28 2024-11-01 大陸商蘇州創勝醫藥集團有限公司 抗-fgfr2b抗體及其用途
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗-FGFR2b免疫偶聯物及其於治療癌症的用途
WO2025130860A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体及其应用
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE179862T1 (de) 1989-07-06 1999-05-15 Univ California Rezeptoren für fibroblasten-wachstumsfaktoren
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトkgfrに対する抗体
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ATE440869T1 (de) 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
CN101357943A (zh) * 2001-10-25 2009-02-04 杰南技术公司 糖蛋白组合物
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7531304B2 (en) 2002-01-31 2009-05-12 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for screening FGFR-4 agonists
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
KR100493460B1 (ko) 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 fgfr2 이성체
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
RU2337107C2 (ru) * 2003-05-02 2008-10-27 Ксенкор, Инк. ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ATE506077T1 (de) * 2003-10-16 2011-05-15 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
DK2330201T3 (en) 2003-10-22 2017-07-24 Keck Graduate Inst PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY
DE602004026470D1 (de) 2003-11-05 2010-05-20 Roche Glycart Ag Fc-rezeptor und effektorfunktion
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
CA2589895A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
RU2492186C2 (ru) * 2005-02-18 2013-09-10 Медарекс Ллс Выделенное анти-cd30 антитело (варианты), хозяйская клетка, способ получения химерного или гуманизированного варианта анти-cd30 антител (варианты), способ ингибирования роста клеток cd30+ и способ ингибирования роста опухолевых клеток, экспрессирующих cd30
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
CA2651755A1 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2007146847A2 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
EP2433966A1 (en) 2006-11-03 2012-03-28 U3 Pharma GmbH FGFR4 antibodies
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
TW200833711A (en) 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2538990T3 (es) 2007-01-24 2015-06-25 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
CN101903534B (zh) 2007-03-23 2014-07-30 翻译基因组学研究院 诊断、分类和治疗子宫内膜癌和初癌的方法
EP2142569A2 (en) * 2007-03-28 2010-01-13 Biogen Idec, Inc. Non-fucosylated antibodies
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
CN101960893B (zh) 2008-03-26 2014-06-04 日本电气株式会社 无线电资源控制方法、无线电台站设备、存储无线电台站控制程序的记录介质及无线电通信系统
WO2009151448A1 (en) * 2008-06-10 2009-12-17 University Of Southern California Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
KR101699432B1 (ko) 2008-11-07 2017-01-24 갤럭시 바이오테크, 엘엘씨 섬유아세포성장인자수용체 2에 대한 모노클로날 항체
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury
PL2486141T3 (pl) * 2009-10-07 2018-07-31 Macrogenics, Inc. Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
ES2743558T3 (es) * 2009-10-14 2020-02-19 Humanigen Inc Anticuerpos de-EphA3
JP2013517282A (ja) 2010-01-14 2013-05-16 イェール ユニバ−シティ− 受容体チロシンキナーゼ(rtk)のインヒビターおよびその使用方法
US9140689B2 (en) 2010-03-14 2015-09-22 Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2603521A4 (en) 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
EP3219731A1 (en) * 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
RU2014128467A (ru) 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
JP2015514708A (ja) * 2012-03-30 2015-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗emp2療法による癌幹細胞の低減
CN104334724B (zh) 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2871236A4 (en) 2012-07-05 2016-03-09 Nat Cancer Ct FGFR2 fusion
WO2014089193A1 (en) 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MX2015015115A (es) 2013-05-01 2016-06-07 Five Prime Therapeutics Inc Metodos de tratamiento de cancer.
JP6696896B2 (ja) 2013-06-13 2020-05-20 ユニバーシティ オブ サウス オーストラリアUniversity of South Australia 前立腺癌を検出する方法
PL3027651T3 (pl) 2013-08-01 2019-08-30 Five Prime Therapeutics, Inc. Afukozylowane przeciwciała anty-fgfr2iiib
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015116868A2 (en) 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR20250034528A (ko) 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
RS67296B1 (sr) 2017-05-16 2025-11-28 Five Prime Therapeutics Inc Anti-fgfr2 antitela u kombinaciji sa sredstvima za hemoterapiju u lečenju karcinoma

Also Published As

Publication number Publication date
HUE043815T2 (hu) 2019-09-30
EP3027651B1 (en) 2019-02-27
KR102825701B1 (ko) 2025-06-27
EP3708583B1 (en) 2022-03-02
HK1220211A1 (en) 2017-04-28
RS58719B1 (sr) 2019-06-28
KR20230047508A (ko) 2023-04-07
ZA201603218B (en) 2019-03-27
RU2016106101A (ru) 2017-09-06
AU2019206039A1 (en) 2019-08-01
US20190175730A1 (en) 2019-06-13
PT3027651T (pt) 2019-05-31
HRP20190502T1 (hr) 2019-05-03
CY1121517T1 (el) 2020-05-29
RU2019125027A3 (me) 2020-02-28
US20250269016A1 (en) 2025-08-28
LT3708583T (lt) 2022-04-11
MX374785B (es) 2025-03-06
PH12019501393A1 (en) 2020-09-14
NZ715201A (en) 2021-12-24
PE20210949A1 (es) 2021-05-24
TWI633120B (zh) 2018-08-21
US20160339100A1 (en) 2016-11-24
TW201536804A (zh) 2015-10-01
PH12016500137B1 (en) 2019-12-04
CL2018002291A1 (es) 2018-09-14
SI3027651T1 (sl) 2019-05-31
DK3027651T3 (en) 2019-04-15
JP2023018049A (ja) 2023-02-07
MX2020009223A (es) 2020-10-14
CL2016000221A1 (es) 2016-07-08
JP2020040955A (ja) 2020-03-19
CY1125443T1 (el) 2024-12-13
LT3027651T (lt) 2019-04-10
CA2915665A1 (en) 2015-02-05
PH12019501393B1 (en) 2022-09-07
EP3708583A1 (en) 2020-09-16
RU2740714C2 (ru) 2021-01-20
RU2019125027A (ru) 2019-08-19
PT3708583T (pt) 2022-05-13
ES2913291T3 (es) 2022-06-01
AU2021245169A1 (en) 2021-11-04
IL243409B (en) 2019-10-31
CN105452296A (zh) 2016-03-30
JP2025118617A (ja) 2025-08-13
TW201906629A (zh) 2019-02-16
PH12021552742A1 (en) 2022-05-23
WO2015017600A1 (en) 2015-02-05
RU2698061C2 (ru) 2019-08-21
US10172937B2 (en) 2019-01-08
DK3708583T3 (da) 2022-05-16
AU2025203545A1 (en) 2025-06-05
ES2719103T3 (es) 2019-07-08
SG11201600767UA (en) 2016-03-30
PL3708583T3 (pl) 2022-06-06
PH12016500137A1 (en) 2016-04-18
SI3708583T1 (sl) 2022-05-31
PE20160190A1 (es) 2016-04-28
KR102516152B1 (ko) 2023-03-31
BR112015032789A2 (pt) 2017-11-07
PL3027651T3 (pl) 2019-08-30
IL243409A0 (en) 2016-03-31
CN105452296B (zh) 2020-09-25
CN112225810B (zh) 2024-10-29
EP3027651A1 (en) 2016-06-08
HUE058243T2 (hu) 2022-07-28
AU2021245169B2 (en) 2025-02-20
CA2915665C (en) 2020-07-28
AU2014296174A1 (en) 2016-01-21
JP7183136B2 (ja) 2022-12-05
MX2016001236A (es) 2016-05-24
CN112225810A (zh) 2021-01-15
US20150050273A1 (en) 2015-02-19
EP4036118A1 (en) 2022-08-03
AU2019206039B2 (en) 2021-07-08
US12465636B2 (en) 2025-11-11
KR20160030578A (ko) 2016-03-18
JP6860342B2 (ja) 2021-04-14
AU2014296174B2 (en) 2019-05-02
US11235059B2 (en) 2022-02-01
JP2016527273A (ja) 2016-09-08
KR20250099279A (ko) 2025-07-01
MY184628A (en) 2021-04-10
US20220168416A1 (en) 2022-06-02
TWI679021B (zh) 2019-12-11
JP2022078080A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
ZA201808451B (en) Anti-fcrh5 antibodies
ZA201603218B (en) Afucosylated anti-fgfr2iiib antibodies
GB201322583D0 (en) Antibodies
SG11201509361TA (en) Novel antibodies
ZA201601437B (en) Antibodies
IL240404B (en) link means
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti- ccl17 antibodies
GB201303507D0 (en) Assays
GB201312226D0 (en) Improved antibodies
GB201318283D0 (en) Antibodies